       Document 0177
 DOCN  M9640177
 TI    Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a
       case-control study.
 DT    9604
 AU    Ammassari A; Linzalone A; Murri R; Marasca G; Morace G; Antinori A;
       Department of Infectious Diseases, Catholic University, Rome,; Italy.
 SO    Scand J Infect Dis. 1995;27(3):235-7. Unique Identifier : AIDSLINE
       MED/96143363
 AB    In order to verify whether fluconazole has a prophylactive effect
       against the occurrence of cryptococcosis in HIV-infected patients and to
       identify other factors capable of increasing or reducing the risk of
       this infection, we arranged a case-control study of 17 patients with
       cryptococcal infection. 34 controls were selected, matched by presence
       of an AIDS-defining event, CD4 cell count, and date of T-cell
       phenotyping. No significant difference in exposure to fluconazole, in
       total days of treatment, or in total dose administered was observed
       between cases and controls. However, control patients took a
       significantly higher average daily dosage of fluconazole and a linear
       tendency in risk reduction (p = 0.04) in relation to increasing dosage
       was observed. Antiretroviral therapy and an average daily fluconazole
       dose exceeding 150 mg both each reduced the risk of a cryptococcal
       infection.
 DE    Adult  Antifungal Agents/*THERAPEUTIC USE  Antigens, Fungal/ANALYSIS
       AIDS-Related Opportunistic Infections/COMPLICATIONS/*DRUG THERAPY
       Case-Control Studies  Cryptococcosis/COMPLICATIONS/*DRUG THERAPY
       Cryptococcus neoformans  CD4 Lymphocyte Count  CD4-Positive
       T-Lymphocytes/IMMUNOLOGY  Dermatomycoses/COMPLICATIONS/DRUG THERAPY
       Female  Fluconazole/*THERAPEUTIC USE  Fungemia/MICROBIOLOGY  Human
       Immunophenotyping  Lung Diseases, Fungal/COMPLICATIONS/DRUG THERAPY
       Male  Meningitis, Cryptococcal/COMPLICATIONS/DRUG THERAPY  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

